Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apyx Medical CorpAPYX · Entity 6609 | Chief Financial Officer | June 11, 2026 | June 15, 2026 |
| PDS Biotechnology CorpPDSB · Entity 7939 | Chief Financial Officer | January 05, 2023 | January 06, 2023 |
| STRATA Skin Sciences, Inc.SSKN · Entity 72980 | Chief Financial Officer | November 13, 2020 | November 13, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apyx Medical Corp
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Option to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.65 · Expires 2036-06-11 | Direct | 132,066 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 132,066 · Balance 132,066 F1: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant.
PDS Biotechnology Corp
Report date January 05, 2023 · Filed January 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.61 · Expires 2033-01-05 | Direct | 161,200 |
Reported balance
After 2023-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-05 · Grant · Acquired 161,200 · Balance 161,200 F1: This option, representing a right to purchase a total of 161,200 shares of Common Stock, will become exercisable on January 5, 2024, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, representing a right to purchase a total of 161,200 shares of Common Stock, will become exercisable on January 5, 2024, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 5, 2027.
STRATA Skin Sciences, Inc.
Report date November 13, 2020 · Filed November 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SSKN Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.46 · Expires 2030-11-13 | Direct | 150,000 |
Reported balance
After 2020-11-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-11-13 · Grant · Acquired 150,000 · Balance 150,000 F1: The Options shall vest in 3 equal annual installments commencing on November 13, 2021 and continuing through November 13, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options shall vest in 3 equal annual installments commencing on November 13, 2021 and continuing through November 13, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 23:00 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 132,066 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001493152-26-028766 · ownership.xml · derivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,066 Underlying: Common Stock · 132,066 shares Expires 2036-06-11 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:31 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 100,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001641172-25-011475 · ownership.xml · derivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-05-15 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:07 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 50,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001493152-25-002764 · ownership.xml · derivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-15 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty-six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| August 13, 2024 Filed Aug 13, 2024 22:56 UTC | Apyx Medical Corp APYX · Entity 6609 | PurchaseCommon Stock | 5,336 | $1.13 | $6,029.68 |
DisclosureSEC source: 0001493152-24-031725 · ownership.xml · nonDerivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,836 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.12 to $1.13. The reported price in Column 4 is a weighted average price, rounded to the nearest hundredth. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 13, 2024 Filed Mar 3, 2025 21:05 UTC Amendment | Apyx Medical Corp APYX · Entity 6609 | PurchaseCommon Stock | 6,000 | $1.13 | $6,780.00 |
DisclosureSEC source: 0001493152-25-008863 · ownership.xml · nonDerivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 F1 · shares: Reflects the addition of 664 shares that were inadvertently omitted from the Reporting Person's original Form 4. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.12 to $1.13. The reported price in Column 4 is a weighted average price, rounded to the nearest hundredth. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. F1 · balance_after: Reflects the addition of 664 shares that were inadvertently omitted from the Reporting Person's original Form 4. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 21:05 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 150,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001493152-24-002057 · ownership.xml · derivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2034-01-10 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably in two equal installments on December 4, 2025 and December 4, 2026. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 14:00 UTC | Apyx Medical Corp APYX · Entity 6609 | PurchaseCommon Stock | 2,500 | $2.19 | $5,475.00 |
DisclosureSEC source: 0001493152-23-044805 · ownership.xml · nonDerivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.14 to $2.22. The reported price in Column 4 is a weighted average price, rounded to the nearest hundredth. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:59 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 161,200 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001140361-23-000826 · form4.xml · derivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,200 Underlying: Common Stock · 161,200 shares Expires 2033-01-05 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 161,200 shares of Common Stock, will become exercisable on January 5, 2024, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 5, 2027. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 14:10 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Stock | 100 | $9.00 | $900.00 |
DisclosureSEC source: 0001140361-21-041473 · form4.xml · nonDerivative · entry 4 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Daughter Disclosed balance after: 4,075 F1 · kind: Shares acquired on the open market. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 14:10 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Stock | 100 | $9.00 | $900.00 |
DisclosureSEC source: 0001140361-21-041473 · form4.xml · nonDerivative · entry 3 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Son Disclosed balance after: 3,975 F1 · kind: Shares acquired on the open market. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 14:10 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Stock | 400 | $8.90 | $3,560.00 |
DisclosureSEC source: 0001140361-21-041473 · form4.xml · nonDerivative · entry 2 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 F1 · kind: Shares acquired on the open market. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 14:10 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Stock | 2,500 | $9.00 | $22,500.00 |
DisclosureSEC source: 0001140361-21-041473 · form4.xml · nonDerivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,475 F1 · kind: Shares acquired on the open market. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 20:31 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 202,800 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0001140361-21-034999 · form4.xml · derivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,800 Underlying: Common Stock · 202,800 shares Expires 2031-10-19 F1 · derivative.exercise_date: The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4) and the Issuer's 2019 Inducement Plan, as amended. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on October 19, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 13, 2020 Filed Nov 13, 2020 16:40 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Stock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001051514-20-000062 · form4.xml · derivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-11-13 F1 · derivative.exercise_date: The Options shall vest in 3 equal annual installments commencing on November 13, 2021 and continuing through November 13, 2023. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 16:49 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Stock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001051514-19-000132 · form4.xml · derivative · entry 1 HILL MATTHEW C · CIK 0001278675 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 150,000 shares Expires 2029-11-22 F1 · derivative.exercise_date: The Options shall vest in 3 equal annual installments commencing on November 22, 2020 and continuing through November 22, 2022. Read SEC document |
| June 14, 2018 Filed Jun 14, 2018 15:32 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 1,812 | $1.95 | $3,533.40 |
DisclosureSEC source: 0001140361-18-028569 · doc1.xml · nonDerivative · entry 3 HILL MATTHEW C · CIK 0001278675 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| June 14, 2018 Filed Jun 14, 2018 15:32 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 4,542 | $1.96 | $8,902.32 |
DisclosureSEC source: 0001140361-18-028569 · doc1.xml · nonDerivative · entry 2 HILL MATTHEW C · CIK 0001278675 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,188 Read SEC document |
| June 14, 2018 Filed Jun 14, 2018 15:32 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 3,646 | $1.97 | $7,182.62 |
DisclosureSEC source: 0001140361-18-028569 · doc1.xml · nonDerivative · entry 1 HILL MATTHEW C · CIK 0001278675 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,646 Read SEC document |
| May 23, 2018 Filed May 24, 2018 16:07 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSTRATA Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001140361-18-025504 · doc1.xml · derivative · entry 1 HILL MATTHEW C · CIK 0001278675 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-05-23 F1 · derivative.exercise_date: Options shall vest in three equal installments over a three year period on each of the following dates: on May 23 2019; May 23, 2020 and on May 23, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.